Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other financing activities (2016 - 2025)

Historic Other financing activities for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q1 2025 value amounting to $15000.0.

  • Lineage Cell Therapeutics' Other financing activities fell 3478.26% to $15000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $15000.0, marking a year-over-year increase of 11079.14%. This contributed to the annual value of $23000.0 for FY2024, which is 3783.78% down from last year.
  • As of Q1 2025, Lineage Cell Therapeutics' Other financing activities stood at $15000.0, which was down 3478.26% from $23000.0 recorded in Q1 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Other financing activities peaked at $1.3 million during Q2 2023, and registered a low of -$162000.0 during Q4 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' median Other financing activities value was $918000.0 (recorded in 2021), while the average stood at $665714.3.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other financing activities skyrocketed by 12834.33% in 2021 and then tumbled by 157272.73% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Other financing activities (Quarter) stood at $917000.0 in 2021, then plummeted by 98.8% to $11000.0 in 2022, then crashed by 1572.73% to -$162000.0 in 2023, then surged by 114.2% to $23000.0 in 2024, then tumbled by 34.78% to $15000.0 in 2025.
  • Its last three reported values are $15000.0 in Q1 2025, $23000.0 for Q1 2024, and -$162000.0 during Q4 2023.